MarketPulse

disease-modifying treatment

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Spinal Cord Injury Market Set to Quadruple as Six Therapies Challenge Treatment Void

Spinal cord injury market projected to grow from $354M to $1.4B by 2034 as six emerging therapies target previously untreated condition.
ABBVNGENclinical trialsmarket growth
GlobeNewswire Inc.GlobeNewswire Inc.··Chemomab Therapeutics Ltd.

Chemomab Clears FDA Hurdle for PSC Drug, Eyes Single Phase 3 Trial Path

Chemomab Therapeutics achieved FDA End-of-Phase 2 approval for nebokitug in PSC treatment, establishing streamlined regulatory pathway with promising Phase 2 data.
CMMBmonoclonal antibodyPhase 3 trial